<DOC>
	<DOC>NCT00093119</DOC>
	<brief_summary>This trial will treat patients previously treated for advanced (metastatic) melanoma (skin cancer) with a new chemotherapeutic medicine. The new chemotherapy will be administered weekly in cycles of three weekly doses followed by one week rest. A minimum of three cycles of therapy will be given to determine the anti-tumor response of the new chemotherapy. Patients may continue to stay on therapy a maximum of 9-12 cycles if treatment shows continuing benefit.</brief_summary>
	<brief_title>Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Confirmed Metastatic Melanoma At least 18 years old No other active malignancy Hemoglobin at least 9 Platelet Count at least 100,000 cells/mm3 ANC at least 1500 cells/mm3 AST &amp; ALT less than 2.5X upper limit of normal Total bilirubin less than 1.5mg/dL Creatine less than 1.5 mg/dL Alkaline phosphatase less than 2.5X upper limit of normal Life expectancy of at least 12 weeks ECOG performance status of 01 Patient must provide informed consent Patient must provide authorization to disclose Evidence of active brain metastases The only evidence of metastasis is lytic or blastic bone metastases Preexisting peripheral neuropathy of NCI Toxicity Criteria Scale of grade greater than 2 Received radiotherapy in last 4wks, except if to a nontarget lesion only Clinically significant concurrent illness Investigator's opinion that patient unlikely to complete study Cytotoxic chemotherapeutic agent treatment or investigational drug within previous 4wks History of allergy/hypersensitivity to study drug Serious Medical Risk Factors determine by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Metastatic Melanoma</keyword>
</DOC>